{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:48:44Z","timestamp":1761518924759},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,1,19]],"date-time":"2009-01-19T00:00:00Z","timestamp":1232323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1007\/s11906-009-0005-x","type":"journal-article","created":{"date-parts":[[2009,1,18]],"date-time":"2009-01-18T07:58:21Z","timestamp":1232265501000},"page":"18-22","source":"Crossref","is-referenced-by-count":21,"title":["The role of incretins in cardiovascular control"],"prefix":"10.1007","volume":"11","author":[{"given":"Derek D.","family":"Mafong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert R.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,1,19]]},"reference":[{"key":"5_CR1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","volume":"29","author":"M. Nauck","year":"1986","unstructured":"Nauck M, Stockmann F, Ebert R, Creutzfeldt W: Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986, 29:46\u201352.","journal-title":"Diabetologia"},{"key":"5_CR2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","volume":"3","author":"D.J. Drucker","year":"2006","unstructured":"Drucker DJ: The biology of incretin hormones. Cell Metab 2006, 3:153\u2013165.","journal-title":"Cell Metab"},{"key":"5_CR3","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1210\/endo.137.7.8770921","volume":"137","author":"B.P. Bullock","year":"1996","unstructured":"Bullock BP, Heller RS, Habener JF: Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996, 137:2968\u20132978.","journal-title":"Endocrinology"},{"key":"5_CR4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1055\/s-2004-826160","volume":"36","author":"C.F. Deacon","year":"2004","unstructured":"Deacon CF: Circulation and degradation of GIP and GLP-1. Horm Metab Res 2004, 36:761\u2013765.","journal-title":"Horm Metab Res"},{"key":"5_CR5","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1210\/endo.140.11.7143","volume":"140","author":"L. Hansen","year":"1999","unstructured":"Hansen L, Deacon CF, Orskov C, Holst JJ: Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999, 140:5356\u20135363.","journal-title":"Endocrinology"},{"key":"5_CR6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1517\/13543784.12.1.87","volume":"12","author":"D.J. Drucker","year":"2003","unstructured":"Drucker DJ: Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2003, 12:87\u2013100.","journal-title":"Expert Opin Investig Drugs"},{"key":"5_CR7","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1074\/jbc.272.7.4108","volume":"272","author":"Y.E. Chen","year":"1997","unstructured":"Chen YE, Drucker DJ: Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. J Biol Chem 1997, 272:4108\u20134115.","journal-title":"J Biol Chem"},{"key":"5_CR8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1055\/s-2002-29087","volume":"110","author":"A. Thum","year":"2002","unstructured":"Thum A, Hupe-Sodmann K, Goke R, et al.: Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4. Exp Clin Endocrinol Diabetes 2002, 110:113\u2013118.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"5_CR9","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/BF00401145","volume":"36","author":"M.A. Nauck","year":"1993","unstructured":"Nauck MA, Kleine N, Orskov C, et al.: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7\u201336 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993, 36:741\u2013744.","journal-title":"Diabetologia"},{"key":"5_CR10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"I.M. Stratton","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HA, et al.: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405\u2013412.","journal-title":"BMJ"},{"key":"5_CR11","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2337\/diacare.22.2.233","volume":"22","author":"M. Coutinho","year":"1999","unstructured":"Coutinho M, Gerstein HC, Wang Y, Yusuf S: The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999, 22:233\u2013240.","journal-title":"Diabetes Care"},{"key":"5_CR12","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.numecd.2006.05.006","volume":"16","author":"A. Ceriello","year":"2006","unstructured":"Ceriello A, Davidson J, Hanefeld M, et al.: Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update. Nutr Metab Cardiovasc Dis 2006, 16:453\u2013456.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"5_CR13","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1185\/030079905X49662","volume":"21","author":"P. Home","year":"2005","unstructured":"Home P: Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes. Curr Med Res Opin 2005, 21:989\u2013998.","journal-title":"Curr Med Res Opin"},{"key":"5_CR14","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.2337\/diacare.21.8.1236","volume":"21","author":"E. Barrett-Connor","year":"1998","unstructured":"Barrett-Connor E, Ferrara A: Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care 1998, 21:1236\u20131239.","journal-title":"Diabetes Care"},{"key":"5_CR15","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2337\/diacare.22.6.920","volume":"22","author":"M. Tominaga","year":"1999","unstructured":"Tominaga M, Eguchi H, Manaka H, et al.: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999, 22:920\u2013924.","journal-title":"Diabetes Care"},{"key":"5_CR16","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","volume":"27","author":"J.B. Buse","year":"2004","unstructured":"Buse JB, Henry RR, Han J, et al.: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628\u20132635.","journal-title":"Diabetes Care"},{"key":"5_CR17","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","volume":"28","author":"R.A. DeFronzo","year":"2005","unstructured":"DeFronzo RA, Ratner RE, Han J, et al.: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092\u20131100.","journal-title":"Diabetes Care"},{"key":"5_CR18","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","volume":"28","author":"D.M. Kendall","year":"2005","unstructured":"Kendall DM, Riddle MC, Rosenstock J, et al.: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1083\u20131091.","journal-title":"Diabetes Care"},{"key":"5_CR19","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1463-1326.2006.00602.x","volume":"8","author":"L. Blonde","year":"2006","unstructured":"Blonde L, Klein EJ, Han J, et al.: Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006, 8:436\u2013447.","journal-title":"Diabetes Obes Metab"},{"key":"5_CR20","first-page":"397","volume":"16","author":"D.J. Goldstein","year":"1992","unstructured":"Goldstein DJ: Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992, 16:397\u2013415.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"5_CR21","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.2337\/diacare.23.10.1499","volume":"23","author":"D.F. Williamson","year":"2000","unstructured":"Williamson DF, Thompson TJ, Thun M, et al.: Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000, 23:1499\u20131504.","journal-title":"Diabetes Care"},{"key":"5_CR22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1185\/030079908X253870","volume":"24","author":"D.C. Klonoff","year":"2008","unstructured":"Klonoff DC, Buse JB, Nielsen LL, et al.: Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008, 24:275\u2013286.","journal-title":"Curr Med Res Opin"},{"issue":"Suppl1","key":"5_CR23","first-page":"475","volume":"49","author":"D.M. Kendall","year":"2006","unstructured":"Kendall DM, Bhole D, Guan X, et al.: Exenatide treatment for 82 weeks reduced C-reactive protein, HbA1C, and body weight in patients with type 2 diabetes mellitus [abstract 784]. Diabetologia 2006, 49(Suppl 1):475.","journal-title":"Diabetologia"},{"key":"5_CR24","first-page":"L374","volume":"265","author":"G. Richter","year":"1993","unstructured":"Richter G, Feddersen O, Wagner U, et al.: GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am J Physiol 1993, 265:L374\u2013L381.","journal-title":"Am J Physiol"},{"key":"5_CR25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1172\/JCI0215595","volume":"110","author":"H. Yamamoto","year":"2002","unstructured":"Yamamoto H, Lee CE, Marcus JN, et al.: Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002, 110:43\u201352.","journal-title":"J Clin Invest"},{"key":"5_CR26","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/00004872-200306000-00012","volume":"21","author":"M. Yu","year":"2003","unstructured":"Yu M, Moreno C, Hoagland KM, et al.: Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003, 21:1125\u20131135.","journal-title":"J Hypertens"},{"key":"5_CR27","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1210\/en.2003-0007","volume":"144","author":"R. Gros","year":"2003","unstructured":"Gros R, You X, Baggio LL, et al.: Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003, 144:2242\u20132252.","journal-title":"Endocrinology"},{"key":"5_CR28","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1124\/jpet.106.100982","volume":"317","author":"T. Zhao","year":"2006","unstructured":"Zhao T, Parikh P, Bhashyam S, et al.: Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006, 317:1106\u20131113.","journal-title":"J Pharmacol Exp Ther"},{"key":"5_CR29","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2337\/diabetes.54.1.146","volume":"54","author":"A.K. Bose","year":"2005","unstructured":"Bose AK, Mocanu MM, Carr RD, et al.: Glucagon-like peptide 1 can directly protect the heart against ischemia\/reperfusion injury. Diabetes 2005, 54:146\u2013151.","journal-title":"Diabetes"},{"key":"5_CR30","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1161\/01.CIR.0000139339.85840.DD","volume":"110","author":"L.A. Nikolaidis","year":"2004","unstructured":"Nikolaidis LA, Elahi D, Hentosz T, et al.: Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004, 110:955\u2013961.","journal-title":"Circulation"},{"key":"5_CR31","doi-asserted-by":"crossref","first-page":"H2401","DOI":"10.1152\/ajpheart.00347.2005","volume":"289","author":"L.A. Nikolaidis","year":"2005","unstructured":"Nikolaidis LA, Elahi D, Shen YT, Shannon RP: Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2005, 289:H2401\u2013H2408.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"5_CR32","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","volume":"117","author":"K. Ban","year":"2008","unstructured":"Ban K, Noyan-Ashraf MH, Hoefer J, et al.: Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2340\u20132350.","journal-title":"Circulation"},{"key":"5_CR33","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/01.CIR.0000120505.91348.58","volume":"109","author":"L.A. Nikolaidis","year":"2004","unstructured":"Nikolaidis LA, Mankad S, Sokos GG, et al.: Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109:962\u2013965.","journal-title":"Circulation"},{"key":"5_CR34","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.cardfail.2006.08.211","volume":"12","author":"G.G. Sokos","year":"2006","unstructured":"Sokos GG, Nikolaidis LA, Mankad S, et al.: Glucagonlike peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006, 12:694\u2013699.","journal-title":"J Card Fail"},{"key":"5_CR35","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/oby.2003.174","volume":"11","author":"A.E. Caballero","year":"2003","unstructured":"Caballero AE: Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res 2003, 11:1278\u20131289.","journal-title":"Obes Res"},{"key":"5_CR36","doi-asserted-by":"crossref","first-page":"E1209","DOI":"10.1152\/ajpendo.00237.2004","volume":"287","author":"T. Nystrom","year":"2004","unstructured":"Nystrom T, Gutniak MK, Zhang Q, et al.: Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004, 287:E1209\u2013E1215.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"5_CR37","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"H.C. Gerstein","year":"2008","unstructured":"Gerstein HC, Miller ME, Byington RP, et al.: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545\u20132559.","journal-title":"N Engl J Med"},{"key":"5_CR38","unstructured":"Miller M: Relationship between glycemia medications and mortality in ACCORD. Presented at the 68th Scientific Sessions of the American Diabetes Association. San Francisco, CA; June 10, 2008."}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-009-0005-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-009-0005-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-009-0005-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:14:22Z","timestamp":1559420062000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-009-0005-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,19]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["5"],"URL":"https:\/\/doi.org\/10.1007\/s11906-009-0005-x","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,19]]}}}